Cargando…

Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches

Dimethyl sulfoxide is a well-known and widely used dermal penetration enhancer. Its incorporation in transdermal patches would be highly desirable; however, due to its volatility this is extremely challenging. Here, we report on the feasibility of a dimethyl sulfoxide (DMSO) containing transdermal s...

Descripción completa

Detalles Bibliográficos
Autores principales: Otterbach, Anna, Lamprecht, Alf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999216/
https://www.ncbi.nlm.nih.gov/pubmed/33804395
http://dx.doi.org/10.3390/pharmaceutics13030320
_version_ 1783670730775330816
author Otterbach, Anna
Lamprecht, Alf
author_facet Otterbach, Anna
Lamprecht, Alf
author_sort Otterbach, Anna
collection PubMed
description Dimethyl sulfoxide is a well-known and widely used dermal penetration enhancer. Its incorporation in transdermal patches would be highly desirable; however, due to its volatility this is extremely challenging. Here, we report on the feasibility of a dimethyl sulfoxide (DMSO) containing transdermal system containing estradiol as a model compound. Transdermal patches were prepared from duro-tak(®) 387-2510 containing various DMSO concentrations at different drying temperatures. The resulting patches were analyzed for DMSO content, estradiol and DMSO release, estradiol and DMSO permeation through excised porcine skin, and recrystallization during stability testing. Drying conditions in the range of 35° to 40° allowed a complete polymer solvents removal while retaining significant amounts of DMSO (≤10 mg/patch). Estradiol skin permeation increased 4-fold (Jss = 4.12 µg/cm(−2)·h(−1)) compared to DMSO-negative control (Jss = 1.1 ± 0.2 µg/cm(−2)·h(−1)). As additional benefit, estradiol recrystallization was inhibited by DMSO at even lowest solvent concentrations. Storage stability was limited to 6 months at 25 °C with a surprising discrepancy between DMSO content (significantly lower) and flux (not significantly different). Although the technical feasibility range is relatively narrow, such DMSO-containing matrix-type patches are able to significantly enhance drug permeation through the skin while ameliorating the product stability against recrystallization.
format Online
Article
Text
id pubmed-7999216
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79992162021-03-28 Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches Otterbach, Anna Lamprecht, Alf Pharmaceutics Article Dimethyl sulfoxide is a well-known and widely used dermal penetration enhancer. Its incorporation in transdermal patches would be highly desirable; however, due to its volatility this is extremely challenging. Here, we report on the feasibility of a dimethyl sulfoxide (DMSO) containing transdermal system containing estradiol as a model compound. Transdermal patches were prepared from duro-tak(®) 387-2510 containing various DMSO concentrations at different drying temperatures. The resulting patches were analyzed for DMSO content, estradiol and DMSO release, estradiol and DMSO permeation through excised porcine skin, and recrystallization during stability testing. Drying conditions in the range of 35° to 40° allowed a complete polymer solvents removal while retaining significant amounts of DMSO (≤10 mg/patch). Estradiol skin permeation increased 4-fold (Jss = 4.12 µg/cm(−2)·h(−1)) compared to DMSO-negative control (Jss = 1.1 ± 0.2 µg/cm(−2)·h(−1)). As additional benefit, estradiol recrystallization was inhibited by DMSO at even lowest solvent concentrations. Storage stability was limited to 6 months at 25 °C with a surprising discrepancy between DMSO content (significantly lower) and flux (not significantly different). Although the technical feasibility range is relatively narrow, such DMSO-containing matrix-type patches are able to significantly enhance drug permeation through the skin while ameliorating the product stability against recrystallization. MDPI 2021-03-01 /pmc/articles/PMC7999216/ /pubmed/33804395 http://dx.doi.org/10.3390/pharmaceutics13030320 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Article
Otterbach, Anna
Lamprecht, Alf
Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title_full Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title_fullStr Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title_full_unstemmed Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title_short Enhanced Skin Permeation of Estradiol by Dimethyl Sulfoxide Containing Transdermal Patches
title_sort enhanced skin permeation of estradiol by dimethyl sulfoxide containing transdermal patches
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999216/
https://www.ncbi.nlm.nih.gov/pubmed/33804395
http://dx.doi.org/10.3390/pharmaceutics13030320
work_keys_str_mv AT otterbachanna enhancedskinpermeationofestradiolbydimethylsulfoxidecontainingtransdermalpatches
AT lamprechtalf enhancedskinpermeationofestradiolbydimethylsulfoxidecontainingtransdermalpatches